Skip to main navigation
  • Contact
  • Careers
  • Home

Karyopharm Test

Menu
  • About
    • Overview
    • Mission
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Sine Technology
  • Drug Candidates
    • Pipeline
    • Oral Selinexor (KPT-330)
    • Oral Verdinexor (KPT-335)
    • Oral KPT-350
    • Oral Dual Inhibitor of PAK4
      and NAMPT (KPT-9274)
    • Investigator Sponsored Trials (IST)
  • Investors
    • Corporate Profile
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management Team
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Financials & Filings
      • SEC Filings
      • Annual Reports and Proxies
      • Quarterly Results
      • Key Ratios
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
      • Dividend History
      • Ownership Profile
    • Analyst Coverage
    • Investor FAQs
    • Contact Us
    • Email Alerts
    • Investigator Sponsored Trials (IST)
  • Publications
    • Papers
    • Posters and Presentations
  • Patients & Caregivers
    • Patients & Caregivers Overview
    • Clinical Trials
    • Resources
  • Contact
  • Careers

SEC Filings

Document Details

Form
4
Filing Date
Jan 9, 2018
Document Date
Jan 8, 2018
Form Description
Statement of changes in beneficial ownership of securities
Filing Group
3,4,5
Company
Karyopharm Therapeutics
Issuer
Karyopharm Ther

Filing Formats

View HTML
Download PDF
Download DOC

Investor Relations

  • Corporate Profile
  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • Financials & Filings
  • Stock Information
  • Analyst Coverage
  • Investor FAQs
  • Contact Us
  • Investigator Sponsored Trials (IST)

Shareholder Tools







  • Facebook
  • Google
  • LinkedIn
  • Twitter
  • Email
  • RSS

USA
Karyopharm Therapeutics

  • Corporate Headquarters:
  • 85 Wells Ave., 2nd floor
  • Newton, MA 02459
  •  
  • Main Phone Number (USA)
  • 617-658-0600

GERMANY
Karyopharm Therapeutics

  • Sitz der Gesellschaft:
  • Karyopharm Europe GmbH
  • Franziska-Bilek-Weg 9
  • 80339 München
  • Germany
  •  
  • Tel.: +49 (0) 89 – 54 84 86-101
  • Fax: +49 (0) 89 – 54 84 86-200
  • About
  • SINE Technology
  • Drug Candidates
  • Investors
  • Publications
  • Patients & Caregivers
  • Careers
  • Contact

© 2018 Karyopharm Therapeutics

Terms of Use Privacy Policy